How Severity Is Staged in Avelumab-Associated Merkel Cell Carcinoma

Understanding Staging in Merkel Cell Carcinoma

General health and science communication has long emphasized the importance of understanding disease severity through standardized staging systems. In oncology, staging provides a framework for describing the extent of cancer, guiding treatment decisions, and informing prognosis. This legacy of clear, structured health information allows patients and clinicians to navigate complex diagnoses with a shared vocabulary. Within this tradition, the staging of Merkel cell carcinoma (MCC)—a rare but aggressive skin cancer—follows established TNM criteria, assessing tumor size, lymph node involvement, and metastasis. Such staging remains critical for evaluating outcomes, including in the context of modern immunotherapies like avelumab, a PD-L1 inhibitor approved for advanced MCC. As therapeutic options expand, the intersection of staging and treatment response becomes increasingly relevant.

Avelumab and Its Role in Advanced Merkel Cell Carcinoma

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). MCC is a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis, associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it carries high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). The severity of MCC in the context of avelumab therapy is staged according to standard MCC staging systems, which assess tumor extent, lymph node involvement, and distant metastasis. Clinical presentation typically involves a rapidly growing, painless, firm skin nodule, often on sun-exposed areas. Diagnosis is confirmed via histopathology and immunohistochemistry, with markers such as cytokeratin 20 and neuroendocrine markers. In the metastatic setting, staging determines prognosis and treatment approach. Avelumab is indicated for metastatic MCC, which corresponds to stage IV disease, where the cancer has spread to distant sites.

Evidence from Clinical Trials and Real-World Outcomes

The approval of avelumab for metastatic MCC was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200 (https://pubmed.ncbi.nlm.nih.gov/29799096/). In Part A of that study, confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune checkpoint inhibitors, including avelumab, offer durable responses and significant clinical benefit in advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case described hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates that while irAEs can occur, they may be manageable without necessarily discontinuing treatment.

Management After Avelumab Failure and Prognostic Factors

For patients who become refractory to avelumab, treatment options are limited. In Europe, approved systemic therapies for MCC are limited to the PD-L1 inhibitor avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, studies have investigated the activity of ipilimumab plus nivolumab in avelumab-refractory MCC. In a retrospective study at three German sites, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG also reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). These findings suggest that alternative checkpoint inhibitor combinations may provide benefit after avelumab failure. The prognosis for patients with avelumab-associated MCC depends on several factors, including response to initial therapy, development of resistance, and management of irAEs. The timeline between avelumab exposure and health outcomes varies. In the JAVELIN Merkel 200 trial, responses were assessed over the treatment period, with confirmed objective responses observed in approximately one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). For those who progress, the timeline to subsequent therapy and response can be months, as seen in the retrospective studies where patients were treated with ipilimumab plus nivolumab after avelumab failure (https://pubmed.ncbi.nlm.nih.gov/33439294/). Immune-related adverse events can occur at any time during treatment, as illustrated by the case of hypercalcemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). In summary, staging of MCC in the context of avelumab therapy follows standard oncologic staging for metastatic disease. Avelumab provides a treatment option with a response rate of about one-third in chemotherapy-refractory patients, but approximately half of patients may progress on immune checkpoint inhibitors. For those who become refractory, combination immunotherapy with ipilimumab and nivolumab shows promise. Management of irAEs, such as hypercalcemia from sarcoidosis, is possible with corticosteroids, allowing continuation of avelumab in some cases. The prognosis remains guarded due to the aggressive nature of MCC, but immune checkpoint inhibitors have improved outcomes for a subset of patients.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

How is Merkel cell carcinoma staged in patients treated with avelumab?

Merkel cell carcinoma (MCC) is staged using the standard TNM system, which evaluates tumor size (T), lymph node involvement (N), and distant metastasis (M). Avelumab is approved for metastatic MCC, which corresponds to stage IV disease. Staging guides prognosis and treatment decisions, and in the context of avelumab therapy, it remains the same as for any MCC diagnosis.

What is the prognosis for patients with avelumab-associated Merkel cell carcinoma?

The prognosis depends on response to avelumab, development of resistance, and management of immune-related adverse events. In clinical trials, about one-third of chemotherapy-refractory patients responded to avelumab, but approximately half of advanced MCC patients may progress on immune checkpoint inhibitors. For those who become refractory, combination immunotherapy with ipilimumab and nivolumab has shown promise. Overall, immune checkpoint inhibitors have improved outcomes for a subset of patients, but the prognosis remains guarded due to the aggressive nature of MCC.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.